ENLV
- Enlivex Therapeutics Ltd.
()
Overview
Company Summary
Enlivex Therapeutics Ltd. (ENLV) is a clinical-stage biotechnology company that focuses on developing immunotherapies to address various life-threatening diseases. The company primarily specializes in developing novel treatments based on its proprietary technology platform called Allocetra.
Enlivex's Allocetra is a unique immunotherapy platform designed to modulate and rebalance the immune system response. The technology enables the production of immunomodulatory drugs that have the potential to provide significant clinical benefits in treating severe and life-threatening inflammatory conditions.
One of Enlivex's lead drug candidates is Allocetra-OT, which is currently being evaluated in clinical trials for the treatment of severe and life-threatening conditions associated with immune hyperactivation, such as sepsis, organ failure, and COVID-19 complications. Allocetra-OT works by rebalancing the immune system, controlling the excessive immune response, and reducing the associated damage caused by the immune system.
In addition to Allocetra-OT, Enlivex is also exploring the use of Allocetra in other potential indications, including solid organ transplant rejection prevention, bone marrow transplant rejection prevention, graft-versus-host disease (GVHD) prevention, and more.
Enlivex Therapeutics aims to address critical medical needs by leveraging its innovative immunotherapy platform to provide potential breakthrough treatments for patients suffering from immune system-related diseases. Through their research and clinical trials, the company strives to improve patient outcomes and transform the way severe inflammatory diseases are treated.